Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,499 across all filing types
Latest filing 2021-10-07 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, and compliance with regulatory rules. It does not contain financial statements or comprehensive financial data but rather updates on the share buyback activity. This fits the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2021-10-07 Chinese
关于控股子公司在研产品F-627项目的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about the progress of a clinical drug development project (F-627) by its subsidiary. It details regulatory milestones such as the acceptance of a marketing authorization application by the European Medicines Agency (EMA), clinical trial results, and a commercialization agreement. The document does not contain financial statements, earnings data, or detailed financial analysis. It is an update on a specific project and related regulatory and commercial developments. The document length is 2242 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-10-07 Chinese
关于回购注销部分限制性股票减少注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from 亿帆医药股份有限公司 regarding the repurchase and cancellation of restricted shares, which results in a reduction of registered capital. It details the board and shareholder approvals, the number of shares repurchased and cancelled, and the adjusted total share capital and registered capital. Additionally, it notifies creditors about their rights to claim debts within a specified period. The content focuses on a share repurchase and capital reduction event, not on financial results, management changes, or regulatory filings. The document length is short (1403 characters), but it contains substantive information about the share repurchase and capital change, not merely an announcement of a report. Therefore, the appropriate classification is a Share Issue/Capital Change (SHA) filing.
2021-09-15 Chinese
上海天衍禾律师事务所关于亿帆医药股份有限公司2021年第一次临时股东大会之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and validity of resolutions passed at the 2021 first extraordinary general meeting (临时股东大会) of Yifan Pharmaceutical Co., Ltd. It details the legal compliance of the meeting's notice, attendance, voting procedures, and results. The document does not contain financial statements or performance data, nor is it a report of financial results or management discussion. It is not an announcement of voting results but a legal opinion on the meeting's legality and procedures. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal opinion related to corporate governance and shareholder meetings, not a direct report or announcement category defined elsewhere.
2021-09-15 Chinese
2021年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2021 first extraordinary general meeting (临时股东大会) of 亿帆医药股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and procedural details of the shareholders' meeting. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a proxy solicitation or investor presentation but specifically reports the voting outcomes of a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is relatively short (2590 characters), but it contains substantive voting results, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA).
2021-09-15 Chinese
关于首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase (buyback) activity. It details the board approval, the number of shares repurchased, prices, and compliance with relevant regulations. It does not contain financial statements or comprehensive financial data but is a disclosure of a capital action (share repurchase). This fits the category of Transaction in Own Shares (POS). The document length is short and focused solely on the repurchase event, confirming it is not a full financial report or other type of filing.
2021-09-08 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.